Ardelyx (ARDX) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ardelyx (ARDX) has outperformed Sana Biotechnology (SANA) over the past year, losing 35.4% versus a loss of 38.4%. Over five years, ARDX leads with a +202.8% price change compared with -86.6% for SANA. Ardelyx is the larger company by market cap ($846.9 million vs $835.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | SANA |
|---|---|---|
| Share price | $3.28 | $2.79 |
| Market cap | $846.86M | $835.22M |
| 1-day change | +0.31% | 0.00% |
| YTD return | -43.91% | -31.45% |
| 1-year return | -35.38% | -38.41% |
| 5-year return | +202.78% | -86.58% |
| Forward P/E | 11.29 | — |
| EPS (TTM) | $-0.23 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $6.55 |
| 52-week low | $3.18 | $2.61 |
| Distance from 52-week high | -60.95% | -57.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +293.29% | +202.15% |
| Average volume | 4.17M | 3.13M |
| Shares outstanding | 258.19M | 299.36M |
| Employees | 489 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
ARDX vs SANA FAQ
Which is bigger, Ardelyx or Sana Biotechnology?
Ardelyx (ARDX) is larger, with a market capitalization of $846.86M compared with $835.22M for Sana Biotechnology (SANA).
Which stock has performed better over the past year, ARDX or SANA?
ARDX returned -35.38% over the past 12 months, compared with -38.41% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Sana Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Ardelyx and Biotechnology: Biological Products (No Diagnostic Substances) for Sana Biotechnology.